Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
Aliagas, E.; Alay, A.; Martinez-Iniesta, M.; Hernandez-Madrigal, M.; Cordero, D.; Gausachs, M.; Pros, E.; Saigi, M.; Busacca, S.; Sharkley, A.; Dawson, A.; Palmero, R.; Padrones, S.; Aso, S.; Escobar, I.; Ramos, R.; Llatjos, R.; Vidal, A.; Varela, M.; Sanchez-Cespedes, M.; Fennell, D.; Munoz-Pinedo, C.; Villanueva, A.; Sole, X.; Nadal, E.
Show abstract
There is no effective therapy for patients with malignant pleural mesothelioma (MPM) who progressed to platinum-based chemotherapy and immunotherapy. Here, we investigate the antitumor activity of CDK4/6 inhibitors using in vitro and in vivo preclinical models of MPM. Based on publicly available transcriptomic data of MPM, patients with CDK4 or CDK6 overexpression had shorter overall survival. Treatment with abemaciclib or palbociclib at 100 nM significantly decreased cell proliferation in all cell models. Both CDK4/6 inhibitors significantly induced G1 cell cycle arrest thereby increasing cell senescence and increased the expression of interferon signaling pathway and tumor antigen presentation process in culture models of MPM. In vivo preclinical studies showed that palbociclib significantly reduced tumor growth and prolonged overall survival in a platinum-naive and platinum resistant MPM mouse model. Treatment of MPM with CDK4/6 inhibitors decreased cell proliferation, mainly by promoting cell cycle arrest at G1 and by induction of cell senescence. Our preclinical studies provide evidence for evaluating CDK4/6 inhibitors in the clinic for the treatment of MPM.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers 95%
- Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death 95%
- Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype 95%
Similar papers in this journal
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 96%
- PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer 95%
- The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer 94%
Similar papers in this journal
- Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies. 94%
- Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in GBM 94%
- High Affinity Chimeric Antigen Receptor with Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms 93%
Similar papers in this journal
- KRAS Inhibition Reverses Chemotherapy Resistance Promoted by Therapy-Induced Senescence-like in Pancreatic Ductal Adenocarcinoma 95%
- Targeting FEN1 to enhance efficacy of PARP inhibition in triple-negative breast cancer 94%
- Chitinase 3-like-1 (CHI3L1) in the Pathogenesis of Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer 94%
Similar papers in this journal
- EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition 95%
- CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis 94%
- The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.